Hypertension and Diabetes and the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET): More ammunition against surrogate end points

Article navigation

Commentary| April 01 1998

Robert M Califf, MD;

Robert M Califf, MD

Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center

Durham, North Carolina

Search for other works by this author on:

PubMed

Christopher B Granger, MD

Division of Cardiology, Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center

Durham, North Carolina

Search for other works by this author on:

PubMed

Address correspondence and reprint requests to Robert M. Califf, MD, Duke Clinical Research Institute, 2024 West Main St., Durham, NC 27705.

Diabetes Care 1998;21(4):655–657

https://doi.org/10.2337/diacare.21.4.655

PubMed:

9571359

Hypertension and Diabetes and the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET): More ammunition against surrogate end points Free